An observational study in Hypertension, sponsored by Xinjiang Medical University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2024-03-28.
Sponsored by Xinjiang Medical University · Observational
The aim of this study was to establish a registration and monitoring system for hypertension in Xinjiang from 2020 to 2030 to obtain real information about patient basic information, patient characteristics, diagnostic test patterns, treatment options, and hospitalization outcomes (including mortality). Treatment complications, hospitalization costs, and end-of-life events (death, major adverse cardiac events, mild adverse cardiovascular events) in patients with hypertension in Xinjiang; and scientific prevention strategies aimed at effectively preventing the onset of hypertension; Guidelines in clinical practice recommend, analyze and develop effective treatment strategies to optimize management and outcomes for patients with hypertension; and create cost-effective assessment systems.
The aim of the study is to establish a platform for monitoring, clinical research and translational medicine in Xinjiang, which aims to provide a basis for future quality improvement and research, and to promote efforts to improve the prognosis of patients with hypertension, and to translate research into improved care for patients, thereby reducing Morbidity and mortality associated with hypertension.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's planned enrollment of 50,000 is above the median of 210 across 1,359 observational studies indexed under Hypertension.
Browse Hypertension studies →Xinjiang Medical University is the lead sponsor of 20 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
A patient diagnosed with primary hypertension who was admitted to the First Affiliated Hospital of Xinjiang Medical University
Exclusion Criteria:
Other: Standard therapy
Individualized blood pressure reduction program
Resistant hypertension
Time frame: 10 years of follow-up Resistant hypertension occurred during this period
Death (all-cause mortality, mortality from hypertension complications)
Time frame: 10 years of follow-up deaths occurred during this period
Major adverse cardiovascular events
Time frame: 10 years of follow-up deaths occurred during this period
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xinjiang Medical University